 |
 |

Appendix: Problems in the Design and Reporting of Trials of Antifungal Agents Encountered During Meta-analysis
Helle Krogh Johansen, MD, DMSc;
Peter C. Gøtzsche, MD, DMSc
JAMA. 1999;282:1756-1757.
 |
 |
| Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings. |
|
 |
 |
APPENDIX
We identified 12 relevant reports,1-12 of which 3 were subsequently excluded. A trial in which only 12 patients received nystatin had failed due to serious problems with compliance9; another reported only the number of "Candida-free" days (which was 18 for both nystatin and placebo)10; the third report was a duplicate publication.11 Of the 9 included trials, 1 was published as an abstract only.8
The drugs were given prophylactically in 7 trials and as treatment in 2.6, 12 Acute leukemia was the most common disease in 6 trials; 1 trial concerned patients receiving a liver transplant7; 1, critically ill surgical and trauma patients3; and 1, patients with acquired immunodeficiency syndrome.12 Nystatin was compared with placebo in 3 trials1-3 and with fluconazole in 64-8,12; all drugs were given orally. In total, 537 patients received nystatin, 147 . . . [Full Text of this Article]
Author Affiliations: The Nordic Cochrane Centre, Rigshospitalet, Copenhagen, Denmark.
CiteULike Connotea Del.icio.us Digg Reddit Technorati Twitter
What's this?
RELATED ARTICLES
Problems in the Design and Reporting of Trials of Antifungal Agents Encountered During Meta-analysis
Helle Krogh Johansen and Peter C. Gøtzsche
JAMA. 1999;282(18):1752-1759.
ABSTRACT
| FULL TEXT
Fair Conduct and Fair Reporting of Clinical Trials
Drummond Rennie
JAMA. 1999;282(18):1766-1768.
EXTRACT
| FULL TEXT
|